Overview
Indications
Limitations of Use: Febuxostat tablets are xanthine oxidase (XO) inhibitor indicated for the chronic management of hyperuricemia in adult patients with gout who have an inadequate response to a maximally titrated dose of allopurinol, who are intolerant to allopurinol, or for whom treatment with allopurinol is not advisable.Febuxostat tablets are not recommended for the treatment of asymptomatic hyperuricemia.
Boxed Warning
FDA Black Box Warning
[ Gout patients with established cardiovascular (CV) disease treated with febuxostat had a higher rate of CV death compared to those treated with allopurinol in a CV outcomes study see Warnings and Precautions (5.1)]. see Indications and Usage (1)]. [ Consider the risks and benefits of febuxostat wh
Contraindications
When this intervention should not be used
7 [see Drug Interactions ()] Febuxostat is contraindicated in patients being treated with azathioprine or mercaptopurine.
Indications & Related Conditions
Conditions associated via SNOMED clinical relationships
Administration & Protocol
Dosing, route, and treatment protocol
Detailed dosage and administration information is available in the full FDA drug label.
View full prescribing information on DailyMedMonitoring & Follow-Up
Biomarkers relevant to this intervention via related conditions
No monitoring biomarkers have been mapped yet. Biomarker-intervention linkages are derived through related conditions and will expand as the knowledge graph grows.
Clinical Trials
13 trials linked to this intervention
Recent Trials
Effect of Dotinurad in Hyperuricemia With Hypertension
Effect of Allopurinol and Febuxostat on Urinary 2,8-Dihydroxyadenine Excretion
CSP594 Comparative Effectiveness in Gout: Allopurinol vs. Febuxostat
Febuxostat Versus Allopurinol on Hepatic Steatosis in MAFLD Patients
Effects of Hyperuricemia Reversal on Features of the Metabolic Syndrome
Research Evidence
Published studies and systematic reviews
Research data from MEDLINE/PubMed
Benefits & Expected Outcomes
Benefits, expected outcomes, efficacy data, and NNT (Number Needed to Treat) are pending physician authorship and evidence review.
Risks & Side Effects
Adverse reaction and safety data for this drug is sourced from the FDA-approved label.
View adverse reactions & drug interactions on DailyMedRelated Symptoms
Symptoms associated with conditions this intervention addresses
No related symptoms have been mapped yet. Symptom linkages are derived through associated conditions.
Alternatives & Comparisons
Alternative treatments, comparison data, and clinical decision support are pending physician authorship.
This information is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult with a qualified healthcare provider regarding any medical condition or treatment plan.
Do not start, stop, or change any treatment without consulting your healthcare provider.
Quick Facts
- Type
- Substance / Medication
- Fully Specified Name
- Febuxostat (substance)
- SNOMED CT
- 441743008
- UMLS CUI
- C0249529
- RxNorm CUI
- 73689
- Labeler
- Novadoz Pharmaceuticals LLC
Clinical Data
This intervention maps to 1 entities in the Ltrl knowledge graph.
Data is sourced from SNOMED CT, UMLS, and the Ltrl clinical knowledge graph. Content sections marked as pending require physician authorship. Consult a healthcare provider before starting any treatment.